U heeft thema's geselecteerd om te volgen, maar deze worden niet opgeslagen zolang u niet bent ingelogd. Login of registreer om deze thema's te blijven volgen.

Home > Node >

Innovative Medicines Initiative (IMI): 7th Call for proposals (H2020-JTI-IMI2-2015-07)



Action Types:

  • RIA – Research and Innovation Actions
  • CSA – Coordination and Support Actions


  • Validation of translational imaging methods in drug safety assessment (TRISTAN)
  • Identification of druggable targets modulating misfolded proteins in Alzheimer’s and Parkinson’s diseases
  • Pathological neuron-glia interactions in neuropathic pain
  • Dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention
  • A comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule development for children with cancer

Topics under the Big Data for Better Outcomes programme:

  • Coordination and support action (CSA) for the big data for better outcomes programme
  • Increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients 

Please read the IMI2 Call 7 Topics Text for full details of these topics, including the budget breakdown and the General Conditions for the Call for proposals


From EFPIA companies: EUR 46 802 000 (indicatief)

From the IMI2 JU: EUR 46 802 000 (indicatief)

Meer info: IMI2 Call 7 Topics Text (i.h.b. p. 78 e.v.) 


List of countries and applicable rules for funding

By way of derogation from Article 10(1) of Regulation (EU) No 1290/2013, only the following participants shall be eligible for funding from the Innovative Medicines Initiative 2 Joint Undertaking:

a) legal entities established in a Member State or an associated country, or created under Union law; and

b) which fall within one of the following categories:

i. micro, small and medium-sized enterprises and other companies with an annual turnover of EUR 500 million or less, the latter not being affiliated entities of companies with an annual turnover of more than 500 million; the definition of ‘affiliated entities’ within the meaning of Article 2(1)(2) of Regulation (EU) No 1290/2013 shall apply mutatis mutandis;

ii. secondary and higher education establishments;

iii. non-profit organisations, including those carrying out research or technological development as one of their main objectives or those that are patient organisations.

c) the Joint Research Centre;

d) international European interest organisations.

In accordance with Article 10(2) point (a) of the Regulation (EU) No 1290/2013, in case of participating legal entity established in a third country, that is not eligible for funding according to point (a) above, funding from the IMI2 JU may be granted provided the participation is deemed essential for carrying out the action by the IMI2 JU.

Meer info:

Info & contact

Link naar de call-webpagina

Webinars on IMI 2 Calls 7 & 8 (11 januari - 29 januari 2016)

Contactgegevens IMI Programme Office:

​Contactgegevens Nationaal Contacpunt:

Your VLEVA-contact for this theme

Create an account

Follow us